Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases. In some embodiments, the cancer is selected from the group consisting of a carcinoma, a sarcoma, a lymphoma, Hodgekins disease, a melanoma, a mesothelioma, Burkitts lymphoma, a nasopharyngeal carcinoma, a leukemia, and a myeloma.
